evorpacept   Click here for help

GtoPdb Ligand ID: 11592

Synonyms: ALX-148 | ALX148
Compound class: Peptide or derivative
Comment: Evorpacept (ALX148) is a dimeric CD47-binding fusion protein that contains two copies of a modified SIRPα D1 domain fused to an inactive human IgG1 Fc domain [1]. It blocks the CD47-SIRPα "don't eat me" (anti-phagocytic) signal.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
The potential of ALX148 to enhance innate and adaptive antitumour immunity is under investigation [1], including its potential to augment the efficacy of exisiting immunotherapeutics.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04755244 A Study of ALX148 With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) Phase 1/Phase 2 Interventional ALX Oncology Inc.
NCT04675294 ALX148 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03). Phase 2 Interventional ALX Oncology Inc.
NCT04675333 ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) Phase 2 Interventional ALX Oncology Inc.